small integral membrane protein 43Genealiases: NEMEP · TMEM155
Q-omics provides the consensus-scored SMIM43 profile across patient tissues and cancer cell-line models. SMIM43 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SMIM43 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SMIM43 RNA expression shows 14,981 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where SMIM43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM43 survival associations across molecular data types. SMIM43 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM43 RNA expression–survival associations across cancer types. High SMIM43 expression shows unfavorable associations in KIRP, ACC and LIHC, but favorable associations in SKCM, HNSC and LGG. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SMIM43 RNA expression.
This table summarizes SMIM43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM43 shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC, HNSC, THCA and BRCA. The KIRC box plot shows higher SMIM43 RNA expression in tumor versus normal tissue (log2 FC = +1.063, t-test p < 0.001).
This table shows molecular features associated with SMIM43 in patient tissues and cancer cell lines. In patient samples, SMIM43 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM43 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
